Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thalidomide: Report of six cases of total remission

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 48, Issue 2, 2006, Pages 109-112

  Caseiro, Marcos Montani ^a,b  

^a UNILUS   (Brazil)

^b NONE   (Brazil)

Author keywords

Hepatitis C; Thalidomide

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON; RIBAVIRIN; THALIDOMIDE;

ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FUNCTION TEST; REMISSION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 33646675327     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/S0036-46652006000200011     Document Type: Article

References (87)

1. ABBAS, Z.E.T. MOATTER - Interleukin (IL) 1beta and IL-10 gene polymorphism in chronic hepatitis C patients with normal or elevated alanine aminotransferase levels. J. Pak. med. Ass., 53: 59-62, 2003.
2. ALTER, M.J.; KUHNERT, W.L. & FINELLII, L. - Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. M.M.W.R., 52(RR 03): 1-16, 2003.
3. ANDREONE, P.; CURSARO, C.; GRAMENZI, A. et al. - A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver, 16: 207-210, 1996.
4. ANDREONE, P.; GRAMENZI, A.; CURSARO, C. et al. - Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. J. viral Hepatitis, 11: 69-73, 2004.
5. ANGELICO, M.; CEPPARULO, M.; ANGELICO, F. et al. - A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. Aliment. Pharmacol. Ther., 19: 339-347, 2004.
6. ANGELICO, M.; CEPPARULO, M.; BARLATTANI, A. et al. - Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. Aliment. Pharmacol. Ther., 14: 1459-1467, 2000.
7. BARNARD, D.L. - Pegasys (Hoffmann-La Roche). Curr. Opin. invest. Drugs, 2: 1530-1538, 2001.
8. BARREIROS, A.P.; SCHLAAK, J. F.; GERKEN, G. et al. - Interleukin-2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin. Europ. J. clin. Invest., 33: 628-629, 2003.
9. BATTEGAY, M.; HOLDENER, M.; NAEF, M. & WERNIL, M. - Human immunodeficiency and hepatitis C virus coinfection influenced by interferon-gamma. Immunol. Lett., 71: 141-142, 2000.
10. BEAN, P. - The use of alternative medicine in the treatment of hepatitis C. Amer. clin Lab., 21: 19-21, 2002.
11. BERGER, T.G.; HOFFMAN, C. & THIEBERG, M.D. - Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J. Amer. Acad. Derm., 33: 837-838, 1995.
12. BOUCHER, E.; GUYADER, D.; JACQUELINET, S. et al. - Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients. Digest. Liver Dis., 32: 29-33, 2000.
13. BOZKAYA, H.; BOZDAYI, A.M.; ASLAN, N. et al. - Circulating IL-2 and IL-10 in chronic active hepatitis C with respect to the response to IFN treatment. Infection, 28: 309-313, 2000.
14. CHEN, W.; LIU, J. & GLUUD, C. - Bile acids for viral hepatitis. Cochrane Database Syst. Rev., (2): CD003181, 2003.
15. COMBE, B. - Thalidomide: new indications? Joint Bone Spine, 68: 582-587, 2001.
16. DANSAKO, H.; NAGANUMA, A.; NAKAMURA, T. et al. - Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. Virus Res., 97: 17-30, 2003.
17. DEUFFIC-BURBAN, S.; WONG, J. B.; VALLERON, A.J. et al. - Comparing the public health burden of chronic hepatitis C and HIV infection in France. J. Hepat., 40: 319-326, 2004.
18. DHARANCY, S.; CANVA, V.; GAMBIEZ, L.; PARIS, J.C. & DESREUMAUX, P. - Hepatic deficiency of interleukin 10 in chronic hepatitis C. Gastroenterology, 119: 1411-1412, 2000.
19. DIGGLE, G.E. - Thalidomide: 40 years on. Int. J. clin. Pract., 55: 627-631, 2001.
20. DOLEV, E. - The thalidomide story and its lessons. Harefuah., 140: 663-667, 2001.
21. EL-SERAG, H.B. - Hepatocellular carcinoma: an epidemiologic view. J. clin. Gastroent., 35 (suppl. 2): S72-78, 2002.
22. ENGLER, S.; FLECHTENMACHER, C.; WIEDEMANN, K.H. et al. - Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. J. viral Hepatitis, 11: 60-68, 2004.
23. FABBRI, C.; MARCHETTO, S.; PEZZOLI, A. et al. - Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients. Europ. J. Gastroent. Hepat., 12: 511-515, 2000.
24. FARGION, S.; FRACANZANI, A.L.; ROSSINI, A. et al. - Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Amer. J. Gastroent., 97: 1204-1210, 2002.
25. FLOREANI, A.; LOBELLO, S.; BRUNETTO, M.; ANELONI, V. & CHIARAMONTE, M. - Colchicine in chronic hepatitis B: a pilot study. Aliment. Pharmacol. Ther., 12: 653-656, 1998.
26. FONG, T.L.; HAN, S.H.; TSAI, N.C. et al. - A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J. Hepat., 28: 369-374, 1998.
27. FRIED, M.W.; SHIFFMAN, M.L.; REDDY, K.R. et al. - Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl. J. Med., 347: 975-982, 2002.
28. FUJIOKA, T.T.; KONDOU, T.; FUKUHARA, A. et al. - Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis C: a pilot study. Hepat. Res., 26: 10-14, 2003.
29. GATELY, M.K. - Interleukin-12: potential clinical applications in the treatment of chronic viral hepatitis. J. viral Hepatitis, 4 (suppl. 1): S33-S39, 1997.
30. GEORGHIOU, P.R. & KEMP, R.J. - HIV-associated oesophageal ulcers treated with thalidomide. Med. J. Aust., 152: 382-383, 1990.
31. GORIN, I.; VILETTE, B.; GEHANNO, P. & ESCANDE, J.P. - Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Lancet, 335: 1343, 1990.
32. GUILERA, M.; FORNS, X.; TORRAS, X. et al. - Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. J. Hepat., 33: 135-141, 2000.
33. HADZIYANNIS, S.J.; SETTE Jr., H.; MORGAN, T.R. et al. - Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. intern. Med., 140: 346-355, 2004.
34. HELLSTRAND, K.; BRUNE, M.; MELLQUIST, V.H. et al. - Histamine and the response to IFN-alpha in chronic hepatitis C. J. Interferon Cytokine Res., 18: 21-22, 1998.
35. IL-12 for hepatitis C. Treatmentupdate, 11: 2-3, 1999.
36. KAPLAN, G. - Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology, 191: 564-568, 1994.
37. KASPRZAK, A.; ZABEL, M.; BICZYSKO, W. et al. - Expression of cytokines (TNF-alpha, IL-1alpha, and IL-2) in chronic hepatitis C: comparative hybridocytochemical and immunocytochemical study in children and adult patients. J. Histochem. Cytochem., 52: 29-38, 2004.
38. KULLAVANUAYA, P.; TREEPRASERTSUK, S.; THONG NGAM, D. et al. - The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results. J. med Ass. Thailand, 84 (suppl.): S462-S468, 2001.
39. KUMADA, H. - Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology, 62: 94-100, 2002.
40. LAUER, G.M. & WALKER, B.D. - Hepatitis C virus infection. New Engl. J. Med., 345: 41-52, 2001.
41. LIU, J.; MANHEIMER, E.; TSUTANI, K. & GLUUD, C. - Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Amer. J. Gastroent., 98: 538-544, 2003.
42. LOGUERCIO, C.; TUCCILLO, C.; CAPORASO, N. et al. - Determination of plasma alpha-glutathione S-transferases in patients with HCV-related chronic infection: its significance and possible clinical relevance. Liver, 18: 166-172, 1998.
43. LOOK, M.P.; GERARD, A.; RAO, G.S. et al. - Interferon/antioxidant combination therapy for chronic hepatitis C: a controlled pilot trial. Antiviral Res., 43: 113-122, 1999.
44. LOUIS, H.; LE MOINE, O.; GOLDMAN, M. & DEVIERE, J. - Modulation of liver injury by interleukin-10. Acta Gastro-enterol. belg., 66: 7-14, 2003.
45. MAHMOOD, S.; YAMADA, G.; NIIYAMA, G. et al. - Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Free Radic. Res., 37: 781-785, 2003.
46. MANNS, M.P.; McHUTCHISON, J.G.; GORDON, S.C. et al. - Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358: 958-965, 2001.
47. MARTIN, J.; NAVAS, S.; QUIROGA, J.A. & CARRENO, V. - Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients. Cytokine, 8: 313-317, 1996.
48. MARTIN, J.; QUIROGA, J.A.; NAVAS, S.; PARDO, M. & CARRENO, V. - Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells. Cytokine, 11: 267-273, 1999.
49. MATTHEWS, S.J. & McCOY, J.A.. - Thalidomide: a review of approved and investigational uses. Clin Ther., 25: 342-395, 2003.
50. MEIERHOFER, C.; DUNZENDORFER, S. & WIEDERMAN, C.J. - Theoretical basis for the activity of thalidomide. BioDrugs, 15: 681-703, 2001.
51. MOSCARELLA, S.; BUZZELLI, G.; ROMANELLI, R.G. et al. - Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results. Liver, 18: 366-369, 1998.
52. MUKHAMEDOV, N.B.; INOIATOVA, F.I.; ARIPOV, A.N. & ARIPOV, O.A. - Combined therapy of chronic hepatitis C in children with phosphogliv. Biomed. Khim., 49: 105-109, 2003.
53. NASCA, M.R.; MICALI, G.; CHEIGH, N.H.; WEST, L.E. & WEST, D.P. - Dermatologic and nondermatologic uses of thalidomide. Ann. Pharmacother., 37: 1307-1320, 2003.
54. NERI, S.; IERNA, D.; ANTOCI, S. et al. - Association of alpha-interferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva med., 42: 187-192, 2000.
55. OKUNO, T.; ARAI, K. & SHINDO, M. - Efficacy of interferon combined glycyrrhizin therapy in patients with interferon-resistant chronic hepatitis C. Nippon Rinsho, 53: 1022-1025, 1995.
56. ORTIZ, V.; OLASO, V.; LOPEZ VIEDMA, B. et al. - The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study. Gastroent. Hepat., 22: 122-126, 1999.
57. OTA, Y.; SASAGAWA, T.; SUZUKI, K. et al. - Vitamin E supplementation increases polyunsaturated fatty acids of RBC membrane in HCV-infected patients. Nutrition, 20: 358-363, 2004.
58. OU-YANG, P.; HWANG, L.H.; TAO, M.H.; CHIANG, B.L. & CHEN, D.S. - Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells. J. med. Virol., 66: 320-328, 2002.
59. PORCARO, G.; SANNINO, C.; MASTROIANNI, M. et al. - Ursodeoxycholic acid in the therapy of chronic hepatitis after treatment with interferon. Minerva med., 91: 141-145, 2000.
60. POUPON, R.E.; BONNAND, A.M.; QUENEAU, P.E. et al. - Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon. Scand. J. Gastroent., 35: 642-649, 2000.
61. PROHASKA, W. & KLEESIEK, K. - Treatment of chronic hepatitis C with inosine pranobex. Lancet, 338: 390-391, 1991.
62. RASI, G.; PIERIMARCHI, P.; SINIBALDI-VALLEBONA, P.; COLELLA, F. & GARACI, E. - Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. Int. Immunopharmacol., 3: 1169-1176, 2003.
63. REYES-TERAN, G.; SIERRA-MADERO, J.G.; MARTINEZ DEL CERRO, V. et al. - Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. Aids, 10: 1501-1507, 1996.
64. RHODEN, E.L.; PEREIRA-LIMA, J.; RHODEN, C.R. et al. - The role of colchicine in prevention of hepatic cirrhosis induced by carbon tetrachloride. Hepatogastroenterology, 46: 1111-1115, 1999.
65. ROCKEY, D.C. - Hepatic fibrogenesis and hepatitis C. Semin. Gastrointest. Dis., 11: 69-83, 2000.
66. ROLLIER, C.; DEPLA, E.; DREXHAGE, J.A. et al. - Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J. Virol., 78: 187-196, 2004.
67. ROSSI, S.J. & WRIGHT, T.L. - New developments in the treatment of hepatitis C. Gut, 52: 756-757, 2003.
68. SARTORI, M.; ANDORNO, S.; RIGAMONTI, C. & BOLDORINI, R. - Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig. Liver Dis., 33: 157-162, 2001.
69. TAKAHARA, T.; SUGIYAMA, K.; ZHANG, L.P. et al. - Cotreatment with interferon-alpha and -gamma reduces liver fibrosis in a rat model. Hepat. Res., 28: 146-154, 2004.
70. THALIDOMIDE and wasting. Posit. aware, 4: 5, 1995.
71. THALIDOMIDE for diarrhea. GMHC Treat Issues, 10: 9, 1996.
72. THIBAULT, V.; DELAUGERRE, C.; CALVEZ, V. et al. - Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial. Hepatology, 35: 238-239, 2002.
73. THIELE, D.L.; DUCHARME, L.; CUNNINGHAM, M.R. et al. - Steroid therapy of chronic hepatitis: characteristics associated with response in anti-hepatitis C virus-positive and -negative patients. Amer. J. Gastroent., 91: 300-308, 1996.
74. THULUVATH, P.J.; MAHESHWARI, A.; MEHDI, J. et al. - Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C. Gut, 53: 130-135, 2004.
75. THULUVATH, P.J.; PANDE, H. & MAYGERS, J. - Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin. Dig. Dis. Sci., 48: 594-597, 2003.
76. TILLMANN, H.L. & MANNS, M.P. - GB virus-C infection in patients infected with the human immunodeficiency virus. Antiviral Res., 52: 83-90, 2001.
77. TSAI, N.C.; SHIMODA, N.; WONG, L. et al. - A novel treatment of patients with chronic hepatitis C. Hawaii med. J., 58: 85-88, 1999.
78. VAN THIEL, D.H.; FARUKI, H.; FRIEDLANDER, L. et al. - Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology, 42: 907-912, 1995.
79. VERBON, A.; JUFFERMANS, N.P.; SPEELMAN, P. et al. - A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob. Agents Chemother., 44: 2286-2290, 2000.
80. WALKER, M.P.; APPLEBY, T.C.; ZHONG, W.; LAU, J.Y. & HONG, Z. - Hepatitis C virus therapies: current treatments, targets and future perspectives. Antivir. Chem. Chemother., 14: 1-21, 2003.
81. WRIGHT, H.I.; GAVALER, J.S.; BADDOUR, N. & VAN THIEL, D.H. - Granulocyte colony stimulating factor (G-CSF) combined with alpha-interferon for the treatment of liver allograft recipients with viral hepatitis. J. Hepat., 21: 915-916, 1994.
82. WU, K.L. & SONNEVELD, P. - Thalidomide: new uses for an old drug. Ned. Tijdschr. Geneeskd., 146: 1438-1441, 2002.
83. YOULE, M.; CLARBOUR, J.; FARTHING, C. et al. - Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Brit. med. J., 298: 432, 1989.
84. YOUNOSSI, Z.M.; MULLEN, K.D.; HODNICK, S. et al. - Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C. J. clin. Gastroent., 36: 427-430, 2003.
85. ZEUZEM, S. & CARRENO, V. - Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res., 52: 181-188, 2001.
86. ZEUZEM, S.; HOPF, U.; CARRENO, V. et al. - A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology, 29: 1280-1287, 1999.
87. ZHOU, S.; LIU, R.; BAROUDY, B.M.; MALCOLM, B.A. & REYES, G.R. - The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology, 310: 333-342, 2003.